The New Year marks the beginning of a milestone year for Cancer Immunology Research as the journal turns 10 in 2023. Since the inaugural print issue of Cancer Immunology Research, in July 2013, the field of cancer immunology has grown at a breathtaking pace, and we are optimistic that there are even greater advances to come in the next 10 years.

The Journal was launched at a time when it was becoming increasingly clear that modulating the immune system had the potential to yield remarkable responses for some patients with cancer refractory to all other treatments. The first immune checkpoint inhibitor, the CTLA4-specific mAb ipilimumab, had been recently approved by the FDA for treating metastatic melanoma and numerous other promising immunotherapeutics were in clinical development. In the intervening years, immunotherapy has become a new pillar of cancer care. Paving the way for this shift in cancer treatment paradigms was...

You do not currently have access to this content.